Directly observed therapy (DOT): From tuberculosis to HIV;La thérapie sous observation directe (DOT): De la tuberculose au VIH

Revue d'Epidemiologie et de Sante Publique

Volumn 54, Issue 1, 2006, Pages 73-89

  Machouf, N ^a,b   Lalonde, R G ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Bureau 1130   (Canada)

Author keywords

Directly observed therapy (DOT); Highly active antiretroviral therapy (HAART); HIV infection

Indexed keywords

DATA ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; EUROPE; FEASIBILITY STUDY; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; MEDLINE; NORTH AMERICA; PATIENT CARE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; REVIEW; TUBERCULOSIS; VIREMIA; VIRUS LOAD;

EID: 33645576282     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0398-7620(06)76696-2     Document Type: Article

References (75)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO. Fuhrer J. Satten GA. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001; 15: 1369-77.
3. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160: 659-65.
4. Paterson DL, Swindells S, Mohr J, Brester M. Vergis EN. Squier C. et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
5. Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, et al. AdICoNA Study Group. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 (suppl 3): S128-31.
6. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence on highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30: 105-10.
7. Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31 (suppl 3): S154-7.
8. Maggiolo F, Ripamonti D, Gregis G. Quinzan G. Callegaro A. Arici C, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naïve HIV-1 infected patients. Antivir Ther 2003; 8: 339-46.
9. Hsieh SM, Hung CC, Lu PL, Chen MY, Chang SC. Preliminary experience of adverse drug reaction, tolerability, and efficacy of a once-daily regimen of antiretroviral combination therapy. J Acquir Immune Defic Syndr 2000; 24: 287-8.
10. McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV positive men. AIDS Care 2000; 12: 399-404.
11. Andrade A, Davis H, Celano S, Cheever L, Wu A, Skolasky RL, et al. Intervention trial using a novel electronic device in HAART initiators: impact of cognitive dysfunction. 8th Conference on Retroviruses and Opportunistic Infections, 2001, Chicago, IL, USA.
12. Gifford AL, Groessl EJ. Chronic Disease Self-management and adherence to HIV medications. J Acquir Immune Defic Syndr 2002; 31 (suppl 3): S163-6.
13. Routy JP, Machouf N, Edwardes MD, Brenner BG, Thomas R, Trottier B, et al. Influence of viral load on the transmission of drug-resistant (DR) and wild type (WT) HIV variants: comparison of resistance between chronically-infected (CI) and recently-infected (RI) patients. AIDS 2004; 18: 2305-12.
14. Leigh-Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral treated population. J Infect Dis 2003; 187: 683-6.
15. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
16. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14: F17-23.
17. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354: 729-33.
18. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1999; 279: 1977-83.
19. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002; 29: S2-10.
20. Réseau Juridique Canadien VIH-SIDA. L'injection de drogue et le VIH/SIDA : questions juridiques et éthiques. Montréal : Santé Canada, 1999 : 132 p.
21. Stenzel MS, McKenzie M, Mitty JA, Flanigan TP. Enhancing Adherence to HAART: a pilot program of Modified Directly Observed Therapy. AIDS Read 2001; 11: 317-28.
22. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169: 656-61.
23. Weis SE, Foresman B, Matty KJ, Brown A, Blais FX, Burgess G, et al. Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: a comparative analysis. Int J Tuberc Lung Dis 1999; 3: 976-84.
24. Martin J, Sabugal GM, Rubio R, Sainz-Maza M, Blanco JM, Alonso JL, et al. Outcomes of a health education intervention in a sample of patients infected by HIV, most of them injection drug users: possibilities and limitations. AIDS Care 2001; 13: 467-73.
25. Mitty JA, McKenzie M, Stenzel M, Flanigan T, Carpenter CC. Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA 1999; 282: 1334.
26. Woodward WC. Should Directly Observed Therapy be considered for treatment of HIV? JAMA 1996; 276: 1956.
27. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 1998; 10: 297-312.
28. WHO. Treatment for tuberculosis. Guidelines for national programmes. Geneva: World Health Organization, 1997.
29. WHO. DOTS-plus strategy for MDR-TB. Geneva: World Health Organization, 2002. http://www.who.int/ gtb/policyrd/DOTSplus.htm
30. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000; 355: 1245-50.
31. Bayer R, Stayton C, Desvarieux M, Healton C, Landesman S, Tsai WY. Directly observed therapy and treatment completion for tuberculosis in the United States: is universal supervised therapy necessary? Am J Public Health 1998; 88: 1052-8.
32. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. The Cochrane Library, 2004: volume 1.
33. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998; 352: 1340-3.
34. Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the directly observation component of DOTS for tuberculosis: a randomized controlled trial in Pakistan. Lancet 2001; 357: 664-9.
35. Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed izoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend 2002; 66: 283-93.
36. Kamolratanakul P, Sawert H, Lertmaharit S, Kasetjaroen Y, Akksilp S, Tulaporn C, et al. Randomised controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999; 93: 552-7.
37. Harries AD, Hargreaves NJ, Chimzizi R, Salaniponi FM. Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential. Bull World Health Organ 2002; 80: 464-9.
38. Gourevitch MN, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 531-40.
39. Babudieri S, Aceti A, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA 2000; 284: 179-80.
40. Fichl M, Rodriguez A, Scerpella E, Monroig R, Thompson L, Rechtine D. Impact of directly observed therapy on outcomes in HIV clinical trials. 8th Conference on Retroviruses and Opportunistic Infections (CROI) 2001, Chicago, IL, USA. Abstract 528.
41. Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T, Graham NM, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis 2002; 34: 511-8.
42. Dieckhaus KD. Adherence to self-administred antiretroviral therapy in incarcerated patients. 40th Annual Meeting of Infectious Disease Society of America (IDSA) 2002, Chicago, IL, USA. Abstract 484.
43. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002; 12: 305-7, 312-6.
44. Lanzafame M, Trevenzoli M, Cattelan AM, Rovere P, Parrinello A. Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr 2000; 25: 200-1.
45. Bryant A, Collingham J, Till M, Garcia P. Virologic and clinical outcomes in HIV-infected pregnant women: directly observed therapy can overcome barriers to care. 11th Conference on Retroviruses and Opportunistic Infections (CROI) 2004, San Francisco, CA, USA. Abstract 922.
46. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend 1995; 37: 261-9.
47. Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V, Gute P. A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Med 2000; 1: 162-3.
48. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy improves rates of viral suppression compared to standard care or an intensive adherence intervention. IDSA 40th annual meeting 2002, USA. Abstract 489.
49. Conway B, Prasad J, Reynolds R, Farley J, Jones M, Jutha S, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004: 38: S402-8.
50. Therrien R, Rouleau D, Côté P, Beauchamp B, Vézina S, Maari F. Évaluation du processus d'implantation d'une thérapie antirétrovirale directement observée (TADO) auprès d'utilisateurs actifs de cocaïne par injection à Montréal. Canadian Conference on HIV/AIDS Research (CAHR), avril 2003, Halifax, Canada. Abstract 286P.
51. Lavender KJ, Akai P. Directly observed therapy for delivery of highly active anti-retroviral treatment to inner city human immunodeficiency virus positive patients. First International Conference on Inner City Health, October 2002, Ottawa, Canada.
52. Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health 2003; 80: 416-27.
53. Altice FL, Mezger J, Hodges J, Bruce RD, Springer S, Friedland GH. Directly observed therapy (DOT) for HIV+ drug users. 2nd IAS Conference on HIV Pathogenesis and Treatment, July 2003, Paris, France.
54. Farmer P, Leandre F, Mukherjee J, Gupta R, Tarter L, Kim JY. Community-based treatment of advanced HIV disease: introducing DOT-HAART. Bull World Health Organ 2001; 79: 1145-51.
55. Barker RD, Millard FJ, Nthangeni ME. Unpaid community volunteers: effective providers of directly observed therapy (DOT) in rural South Africa. S Afr Med J 2002; 92: 291-4.
56. Wares DF, Akhtar M, Singh S. DOT for patients with limited access to health care facilities in a hill district of Eastern Nepal. Int J Tuberc Lung Dis 2001; 5: 732-40.
57. Pungrassami P, Johnsen SP, Chongsuvivatwong V, Olsen J. Has directly observed treatment improved outcomes for patients with tuberculosis in Southern Thailand? Trop Med Int Health 2002; 7: 271-9.
58. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Community based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-28.
59. Khanlou H, Kandula VR, Yeh V, Stein TG, Sanchez S, Ricaurte JC, et al. Pilot study of directly observed therapy in highly non-adherent HIV-infected patients in an urban community-based institution. J Acquir Immune Defic Syndr 2003; 33: 651-3.
60. Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, et al. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med 2002; 55: 235-46.
61. Florence E, Garcia F, Plana M, Fumero E, Castro P, Lopez A, et al. Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption. Clin Infect Dis 2004; 39: 569-74.
62. Escobar I, Campo M, Martin J, Fernandez-Shaw C, Pulido F, Rubio R. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother 2003; 37: 775-81.
63. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47: 853-8.
64. Dey P, Roaf E, Collins S, Shaw H, Steele R, Donmall M. Randomized controlled trial to assess the effectiveness of a primary health care liaison worker in promoting shared care for opiate users. J Public Health Med 2002; 24: 38-42.
65. Garner P. What makes DOT work? Directly observed therapy. Lancet 1998; 352: 1326-7.
66. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002; 34: 984-90.
67. Ngamvithayapong J, Yanai H, Winkvist A, Saisorn S, Diwan V. Feasibility of home-based and health center-based DOT: perspectives of TB care providers and clients in an HIV-endemic area of Thailand. Int J Tuberc Lung Dis 2001; 5: 741-5.
68. Liechty CA, Bangsberg DR. Doubt about DOT: antiretroviral therapy for resource-poor countries. AIDS 2003; 17: 1383-7.
69. Greenberg JB, MacGowan R, Neumann M. Linking injection drug users to medical services: Role of street outreach referrals. Health Social Work 1998; 4: 298-309.
70. Thomas R, Machouf N, Lefebvre E. Comparative study: therapeutic regimens in HIV versus HIV-HCV co-infected patients. Communication at the 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, October 2001, Athena, Greece.
71. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-9.
72. Lucas GM, Cheever L, Chaisson R, Moore R. Detrimental effects of continued illicit drug use on the treatment of HIV infection. J Acquir Immune Defic Syndr 2001; 27: 251.
73. Klein MB, Lalonde RG, Suissa S. Hepatitis C (HCV) co-infection is associated with increased morbidity and mortality among HIV-infected patients. 8th Conference on Retroviruses and Opportunistic Infections, February 2001, Chicago, IL, USA. Abstract 569.
74. Bouhnik AD, Chesney M, Carrieri P, Gallais H, Moreau J, Moatti JP, et al.; the MANIF 2000 Study Group. Nonadherence among HIV-infected injecting drug users: The impact of social instability. J Acquir Immune Defic Syndr 2002; 31 (suppl 3): S149-53.
75. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDS 2002; 16: 527-35.